Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3747 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Youngwoo Cho und 15 weiteren Autor:innen. Beteiligte Einrichtung: Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neoplasms, Patient Portals, Pharmacogenetics. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient‐facing portal that delivers multi‐gene PGx results ( CYP2D6 , UGT1A1 , DPYD ) through 33 unique, patient‐friendly summaries. The utility of this tool was prospectively evaluated in an oncology population, where these pharmacogenes impact high‐stakes treatments. Patients enrolled in the PhOCus study (NCT04541381) participated in single‐session evaluations of the tool in‐person or via videoconference, with a pharmacist available for questions and administering pre‐ and post‐surveys that assessed educational impact. Each patient viewed their own previously obtained PGx results. Of 190 eligible patients, 70 responded to solicitations via email, phone, and in‐person, of whom 51 (73%) completed an observed session and completed surveys. Patients spent a median of 13.4 minutes (range 8.1–21.0) navigating YourPGx Oncology. After portal interaction, patients' ability to identify individual efficacy and safety estimates for chemotherapies and pain medications significantly improved, with the proportion accurately recognizing PGx‐informed drug efficacy likelihoods rising from 32% to 72% (Odds Ratio [OR] = 5.8 for the shift from discordant to concordant efficacy knowledge, P < 0.001), and PGx‐related toxicity recognition increasing from 31% to 57% (OR = 3.2, P = 0.01). Our findings show that a customized patient‐facing PGx results portal enhances patient understanding of individual medication efficacy and toxicity likelihoods, highlighting the potential key role of direct‐to‐patient PGx tools to facilitate optimized treatment‐informed care and promote genetically guided shared decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA.
- Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
- Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA.
- Department of Pathology, University of Chicago Medical Center and Biological Sciences, Chicago, Illinois, USA.
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.
- Center for Research Informatics, University of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Sami Elahi, Matthew M Jack, John Campbell, Randall W Knoebel, Larry House, Kiang-Teck J Yeo, Mark J Ratain, Peter H O'Donnell
Förderung
- NHGRI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Cho, Y., Elahi, S., Jack, M. M., Campbell, J., Smith, E., Knoebel, R. W., George, D., House, L., Yeo, K. J., Karrison, T., Volchenboum, S. L., Meltzer, D. O., Szmulewitz, R. Z., Vokes, E. E., Ratain, M. J., & O'Donnell, P. H. (2025). Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3747
Vancouver
Cho Y, Elahi S, Jack MM, Campbell J, Smith E, Knoebel RW, et al. Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3747
BibTeX
@article{Cho2025,
author = {Cho, Youngwoo and Elahi, Sami and Jack, Matthew M and Campbell, John and Smith, Emily and Knoebel, Randall W and George, David and House, Larry and Yeo, Kiang-Teck J and Karrison, Theodore and Volchenboum, Samuel L and Meltzer, David O and Szmulewitz, Russell Z and Vokes, Everett E and Ratain, Mark J and O'Donnell, Peter H},
title = {Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3747}
}
EUVIMED